ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
120.766,57
-1,09%
S&P 500
6.040,04
1,10%
US Dollar vs BRL
6,73785
0,06%
Bitcoin
98.863,92
-0,44%
Brent Oil
73,335
0,07%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Revelation Biosciences Inc (REVB)

  7. Revelation Biosciences Inc (REVB) Notícias

REVB

Revelation Biosciences (REVB)

Revelation Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:REVB
DataHoraFonteTítuloCódigoCompanhia
03/12/202410:38Business WireRevelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross ProceedsNASDAQ:REVBRevelation Biosciences Inc
02/12/202408:00Business WireRevelation Biosciences Inc. Announces FDA Acceptance of Gemini INDNASDAQ:REVBRevelation Biosciences Inc
12/11/202408:00Business WireRevelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug SupplyNASDAQ:REVBRevelation Biosciences Inc
08/11/202418:15Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024NASDAQ:REVBRevelation Biosciences Inc
24/09/202407:00Business WireRevelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10NASDAQ:REVBRevelation Biosciences Inc
03/09/202418:09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:REVBRevelation Biosciences Inc
26/08/202417:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBRevelation Biosciences Inc
21/08/202418:30Business WireRevelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross ProceedsNASDAQ:REVBRevelation Biosciences Inc
09/08/202417:15Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024NASDAQ:REVBRevelation Biosciences Inc
29/07/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:REVBRevelation Biosciences Inc
24/06/202410:00Business WireRevelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker ActivityNASDAQ:REVBRevelation Biosciences Inc
13/06/202410:21Business WireRevelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of GeminiNASDAQ:REVBRevelation Biosciences Inc
10/05/202417:52Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024NASDAQ:REVBRevelation Biosciences Inc
22/03/202417:15Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023NASDAQ:REVBRevelation Biosciences Inc
13/03/202410:00Business WireRevelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
12/03/202410:00Business WireRevelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth ConferenceNASDAQ:REVBRevelation Biosciences Inc
04/03/202411:00Business WireRevelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of GeminiNASDAQ:REVBRevelation Biosciences Inc
13/02/202422:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REVBRevelation Biosciences Inc
13/02/202411:00Business WireRevelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
12/02/202412:19Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REVBRevelation Biosciences Inc
05/02/202418:41Business WireRevelation Biosciences Inc. Announces Closing of $6.2 Million Public OfferingNASDAQ:REVBRevelation Biosciences Inc
02/02/202418:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:REVBRevelation Biosciences Inc
01/02/202408:00Business WireRevelation Biosciences Inc. Announces Pricing of $6.2 Million Public OfferingNASDAQ:REVBRevelation Biosciences Inc
30/01/202417:32Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:REVBRevelation Biosciences Inc
30/01/202411:00Business WireRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)NASDAQ:REVBRevelation Biosciences Inc
23/01/202411:00Business WireRevelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024NASDAQ:REVBRevelation Biosciences Inc
22/12/202319:06Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:REVBRevelation Biosciences Inc
22/12/202315:23Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:REVBRevelation Biosciences Inc
12/12/202318:59Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:REVBRevelation Biosciences Inc
13/11/202318:05Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023NASDAQ:REVBRevelation Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:REVB

Seu Histórico Recente

BIT
SYS
Sys Dat
BIT
CANA
UBS LUX FUND SOLUTIONS -...
LSE
QH92
Morg.st.b.v 25
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados